Epstein-Barr virus-induced lymphoproliferative disease (EBV-LPD) is a potentially lethal complication during the first 6 months after allogeneic bone marrow transplantation (BMT). To determine whether deficiencies of EBV-specific cellular immunity contribute t o EBV-LPD susceptibility and distinguish patients at risk, we performed limiting dilution analysis t o quantify anti-EBV cytotoxic T-lymphocyte precursor (CTLp) frequencies in 26 recipients of unmodified or T cell-depleted (TCD) grafts from EBV-seropositive donors. At 3 months post-BMT (n = 261, only five patients had EBV CTLp frequencies in the range of seropositive normal controls, irrespective of the type of transplant administered. By 6 months post-BMT, 9 of 13 patients tested had EBV CTLp frequencies within the normal range. The time period in which these patients had deficient cellular immunity t o EBV corresponds t o the period in which we have observed EBV-LPD in most prior patients. One patient with a low EBV CTLp
PSTEIN-BARR VIRUS (EBV) is a ubiquitous herpesvi-
rus that infects 95% of people by adulthood.' This virus persists as a latent infection in certain types of epithelial cells, where reactivation and virus replication may intermittently occur, and in B lymphocytes. EBV has the capacity to transform B cells into lymphoblastoid cells, which are morphologically and phenotypically identical to those developed by in vitro transformation of normal B lymphocytes with EBV.* Uncontrolled proliferation of B lymphoblasts occurs in immunocompromised patients, most notably in those with acquired immune deficiency syndrome and congenital defects in immunity and in recipients of solid organ and bone marrow transplants.."" Depletion of a marrow graft with T cell-specific monoclonal antibodies and the use of antithymocyte globulin or certain T cell-specific monoclonal antibodies to enhance immunosuppression posttransplant have been shown to significantly increase the risk of EBVinduced lymphoproliferative disease (EBV-LPD)."SslL EBV-LPD can present as polyclonal or monoclonal disease, the latter of which is rapidly progressive and uniformly fatal."' In bone marrow transplantation (BMT) recipients, most of these lymphomas arise within the first 6 months after trans-frequency at 4 months post-BMT developed an EBV-LPD. Within 2 weeks of receiving an infusion of donor peripheral blood mononuclear cells (PBMC) providing less than 1,200 EBV-specific cytotoxic T-cell precursors, populations of EBVspecific CTL in the circulation were restored t o levels detected in normal seropositive adults. Concurrently, the patient achieved a regression of the EBV-LPD, which has been sustained without further therapy. These studies indicate that recipients of both unmodified and TCD marrow grafts have profound deficiencies of EBV-specific T cell-mediated immunity early posttransplant, and that the period of risk for EBV-LPD closely corresponds t o this interval of severe deficiency. Treatment of one patient with EBV-LPD with marrow donor-derived PBMC induced a rapid expansion of EBV-specific cytotoxic T-cell populations that occurred contemporaneously with the clinical regression of disease. To date, the reconstitution of cell-mediated immune responses against EBV in BMT patients and, specifically in recipients of T cell-depleted (TCD) grafts, has not been characterized in detail. Furthermore, the effects of donor PBMC infusions on the EBVspecific cellular immunity of recipients have not been studied. The purposes of this study were (1) to determine EBV cytotoxic T-lymphocyte precursor (CTLp) frequencies in patients receiving unmodified and TCD BMTs at specific times posttransplant, (2) to ascertain whether qualitative or quantitative deficiencies of EBV-specific immunity could be used to distinguish patients at risk for EBV-LPD, and (3) to characterize the alterations in EBV-specific immunity induced by infusions of donor PBMC administered to marrow graft recipients with EBV+ lymphomas.
(M195)"; four received 15 Gy total body irradiation (TBI) and cyclophosphamide"; and sixteen received TB1 and thiotepa (5 mg/kg for 2 days), followed by cyclophosphamide (60 mgkg/d for 2 days). Recipients of unmodified marrow grafts received graft-versus-host disease (GVHD) prophylaxis consisting of a combination of methotrexate, cyclosporine, and/or methylprednisolone as previously des~r i b e d . '~.~~ For T-cell depletion, the method of Reisner et al" was used. This technique involves sequential removal of mature blood elements from the marrow grafts by differential agglutination with soybean lectin and subsequent removal of residual T cells by sheep red blood cell rosette depletion (SBA-E-). To promote engraftment, 14 of 16 recipients of TCD bone marrow received either antithymocyte globulin (ATG; 15 mgkg per dose; Upjohn, Kalamazoo, MI) administered every other day for five doses starting day 5 post-BMT and daily methylprednisolone (1 to 2 mg/kg) day 5 through day 19, with a subsequent rapid taper (n = 4); or four doses of ATG (30 mgkg per dose on days -2 through -5)." Methylpredisolone 2 mg/ kg was given to each of the latter 10 patients on the days of ATG administration, and posttransplant in one patient. No drug prophylaxis against GVHD was administered.
To assess the period of risk for EBV-LPD in the posttransplant period and to correlate these results with analyses of EBV-specific immunity posttransplant, we reviewed the records of 367 recipients of TCD marrow grafts derived from HLA identical siblings, 96 TCD grafts from unrelated donors, and an additional 192 patients who received unmodified HLA-identical sibling transplants administered from January 1987 to March 1995.
The titers of IgG antibodies specific for the viral capsid antigen (VCA) of the EBV virus were determined on all patients and donors before transplant using standard method~logies.'~ Anti-VCA titers were also determined on a series of normal donors. Individuals with anti-VCA titers 5 1: 10 were considered to be EBV-seronegative. All seropositive normal controls and all bone marrow donors had anti-VCA titers z1:40.
EBV-transformed B lymphoblasroid cell lines (BLCL).
To assess EBV-specific T-cell responses, EBV-transformed lymphoblastoid cell lines were established from each of the bone marrow donors. Aliquots of 30 mL of heparinized blood were collected, and mononuclear cells were isolated by Ficoll-Hypaque density gradient centrifugation. After washing, lo6 PBMC were infected with EBV by incubating them for 48 hours in a medium containing one part of EBV containing supernatant from the marmoset cell line 95-8 and three parts RPMI 1640 containing 15% fetal calf serum (FCS) and 2 kg/ mL phytohemagglutinin (PHA)-16 (Difco Laboratories, Detroit, MI). Thereafter, the cells were centrifuged and transferred to the same medium without PHA-16 for 24 hours and then fed with RPMI 1640 supplemented with 15% FCS, 1% L-glutamine, 1% penicillinstreptomycin, and 1% tylosine (GIBCO, Grand Island, NY) daily until sufficient growth was appreciated. The actively growing EBV-BLCL were maintained in RPMI 1640 with 10% FCS and the above additives.
T-cell isolation. PBMC isolated by Ficoll-Hypaque density gradient centrifugation were allowed to adhere to 75-cm2 plastic tissue culture flasks (Coming, Coming, NY) for 1 hour at 37°C. The adherent monocytes and macrophages were harvested using a cell scraper and were subsequently irradiated and used as feeder cells. The monocyte-depleted peripheral blood lymphocytes (PBL) were then incubated with monoclonal antibodies directed against CD20 and CD56 (Becton Dickinson, San Jose, CA). The CD20+ and CD56' cells were removed by incubating the washed cells with anti-mouse antibody-coated immunomagnetic beads (Dynal, Lake Success, NY) followed by magnetic separation. The T cell-enriched populations were analyzed for their immunophenotype by cytofluoroscopy after incubation with fluorescein-or rhodamine-labeled monoclonal antibodies against CD3, CD4, CD8, CD20, CD56, CD57, and CD45 (Becton Dickinson) using a fluorescence-activated cell analyzer (Becton Dickinson, Mountain View, CA). After removal of CD20+ and CD56' cells, these T cell-enriched populations of PBL contained 81% t 15% CD3+ T lymphocytes (range, 60% to 100%). The majority of the remaining cells were CD56+, CD3-natural killer (NK) cells.
Cell culture. Bulk cultures were set up as follows. Enriched T cells were aliquotted into 24-well plates (Coming) at a concentration of 1 X 106/mL with 1 X lo6 irradiated (3 Gy) adherent cells and 5 X lo4 irradiated (10 Gy) donor/autologous BLCL per well in a total volume of 2 mL. Cell cultures were maintained in RPMI 1640 with 10% FCS and the same additives as described for the BLCL. T cells cultivated in 24-well plates were fed on days 3,6, and 9 by replacing 0.5 mL of supernate with conditioned medium containing 2.5 U/mL recombinant interleukin-2 (IL-2) (Collaborative Biomedical Products, Bedford, MA).
Limiting dilution cultures were established using a modification of the methods of Bourgault et aIx and Langhorne and Lindahl?' Twenty-four replicate wells were used per dilution of T cells in 96-well, U-bottom plates (Nunc-Interned, Kamstrup, Denmark) with 1, OOO irradiated (3 Gy) adherent cells and 2.5 X lo4 irradiated (10 Gy) donor BLCL per well, each well containing a total volume of 200 pL. Twenty-four wells of irradiated BLCL only were used as a control. Cultures were fed with IL-2 on days 3, 6, and 9 by removing 50 pL of culture supernate and replacing with the same conditioned medium containing 2.5 U/mL recombinant IL-2 as described above.
Chromium release assay. Bulk and limiting dilution cultures were assayed simultaneously on day 12 of culture. T cells from bulk cultures were collected from the 24-well plates and resuspended at 1.5 X 106/mL, 0.75 X 106/mL, and 0.38 X 106/mL in RPMI 1640 with 10% FCS. One hundred microliters of each dilution of bulk culture T cells was added in triplicate to 96-well, V-bottom plates (ICN Biomedical, Aurora, OH) for each target cell assayed.
To assay CTLp frequencies, the limiting dilution culture wells were mixed, and equal 35-pL volumes of cells were aliquotted into separate 96-well, V-bottom plates to assess cytotoxicity against each target. RPMI 1640 with 10% FCS was then added (65 pL) to make a total volume of 100 pL.
The following cells were used as targets: donor PHA blasts, donor BLCL, BLCL partially HLA-matched with the donor, allogeneic HLA-different BLCL, and K562, the latter to assess NK activity. Donor PHA blasts were generated 4 days before the cytotoxicity assay. Target cells (2 X IO6) were each incubated with 250 pCi chromium 51 (5'Cr; New England Nuclear, North Billerica, MA) for 2 hours, washed with RPMI, and resuspended at 3O,OOO/mL in RPMI 1640 with 10% FCS. Each target cell preparation (100 pL) was placed in each well containing T cells from either the bulk culture or the limiting dilution cultures for a total volume of 200 pL, and plates were spun at 2,000 rpm for 2 minutes. To determine total 51Cr release, 100 pL of 5% Triton X was added to 100 pL of each 5'Cr-labeled target. Plates were incubated at 37°C and 5% CO, for 4 hours. After the incubation with 5'Cr-labeled targets, 150 pL of supernate was harvested, transferred to microtiter tubes (Continental Labs, San Diego, CA), and counted in a gamma counter. Spontaneous and total release for each target was used to calculate percent specific release using the following formula: were performed as described by Flomenberg et alZ7 using the monoclonal antibody OKT3 (anti-CD3). This antibody was generated from mouse ascites and diluted 1:lO with RPMI. Fifty microliters of blocking antibody was placed into each of the respective wells, for a final antibody dilution of 1:40. Blocking was considered present when there was greater than 20% inhibition of cytotoxicity compared with the wells with responder and target cells alone.
Biostatisrics. Correlations of results of different assays of cellmediated and humoral EBV-specific immunity were computed using the Pearson correlation coefficient. A nonparametric 95% confidence interval (CI) for each population correlation coefficient was generated using the bootstrap resampling procedure.'* The probability of developing EBV-LPD was calculated after an adjustment for competing risks."
RESULTS
The CTLp frequencies detected for T cell-enriched PBL derived from normal EBV-seropositive and -seronegative individuals against autologous EBV-BLCL, autologous PHA blasts, and allogeneic EBV-BLCL are presented in Fig 1. The range of frequencies for CTLp reactive against autologous EBV-BLCL for EBV-seronegative controls was l / 177,900 to undetectable. The mean CTLp frequency against autologous EBV-BLCL for normal EBV-seropositive controls was 1/14,600 (range, 1/1,960 to 1/42,790). While 8 of 10 seropositive donors had CTLp frequencies against allogeneic EBV-BLCL that were less than or equal to 1/100,000, two seropositive donors had values greater than 1/100,000 for fully allogeneic EBV-BLCL. Both EBV-seropositive and -seronegative donors had CTLp frequencies against autologous PHA blasts that were less than 1/100,000.
The lower portion of Fig 2 depicts the cytotoxicity results of bulk cultures of T cells from seropositive and seronegative controls against autologous and allogeneic BLCL targets. The mean percentage of specific lysis directed against the autologous BLCL for EBV-seropositive donors was 39% t-16% (range, 24% to 70%), which differed significantly from the mean of 4.5% t-4.2% (range, 0 to 10%) for EBVseronegative donors ( P < ,001). The highest level of T cell- mediated cytotoxicity observed on EBV-BLCL targets that did not share HLA antigens with the responder cells was 13%. This cut-off point was, therefore, selected for defining positive and negative responses.
The top portion of Fig 2 depicts the log CTLp frequency of normal donors against autologous EBV-BLCL (ordinate) and the percent specific lysis of autologous BLCL (abscissa). There was a strong correlation between log CTLp frequency and the percent specific lysis from bulk cultures (Y = .80; 95% CI, S 7 to .95). The responses of T cells from four normal EBV-seropositive controls and four BMT patients were analyzed after the effector cells were incubated with medium containing a monoclonal antibody against CD3. EBV-specific cytotoxic responses were largely or completely inhibited by treatment of each individual's effector cells with anti-CD3. The mean inhibition by anti-CD3 in EBV-seropositive normal donors was 78% t 17% (range, 54% to 93%) and 82% 2 14% (range, 68% to 100%) in patients.
The log of the EBV CTLp frequencies in BMT patients at 3,6, and 9 months posttransplant are displayed graphically in Fig 3. Twenty-six patients were studied at 3 months after BMT. Of this group, five (19%) had CTLp frequencies in the seropositive range, and six (23%) were in an intermediate range, between that detected for the seropositive and seronegative controls; 15 patients (58%) were in the seronegative range. Thirteen patients were studied 6 months post-BMT, by which time, nine had CTLp frequencies in the seropositive range, one in the intermediate range, and three in the seronegative range. By 6 months post-BMT, five of nine patients who had CTLp frequencies in the intermediate or seronegative range at 3 months had developed CTLp frequencies in the seropositive range. Three patients whose CTLp frequencies were in the seropositive range at 6 months continued to have CTLp frequencies in this range when studied at 9 months post-BMT. The in vitro cytotoxicity against the autologous donor EBV-BLCL in these experiments was virus-specific, because CTLp frequencies for autologous PHA blasts were negligible in the patient and control specimens analyzed.
While the numbers of patients in each group are too few for statistical analysis, the proportion of transplant recipients developing EBV-specific CTLp frequencies in the intermediate or seropositive range by 3 months after an unmodified graft from a matched sibling (4 of 10) or a TCD graft from a matched sibling (5 of 11) or an unrelated donor (two of five) were comparable. Furthermore, as illustrated in Fig 3, the frequencies of EBV-specific CTLp developed by 7 of 16 patients at 3 months and 8 of 11 studied at 6 months after TCD grafts were similar to those detected in recipients of unmodified marrow grafts at the same time period. Figure 4 correlates patient EBV CTLp frequencies from limiting dilution cultures on the ordinate and "Cr release from bulk culture T cells on the abscissa. Bulk culture data were available for all patients except one recipient of an unrelated, TCD graft at 3 months. At 3 months post-BMT, the four patients with CTLp frequencies in the seropositive range also had positive cytotoxicity in bulk culture against the donor BLCL. Cells from two of the six patients with CTLp frequencies in the intermediate range exhibited EBVspecific cytotoxicity in bulk culture, while four lacked detectable cytotoxicity in bulk culture. None of the patients with EBV-CTLp frequencies in the seronegative range had detectable lysis of the donor BLCL. At 6 months post-BMT, T cells from all patients with CTLp frequencies in the seroposi-
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tive and intermediate range exhibited EBV-specific cytotoxicity; the three patients with CTLp in the seronegative range also lacked cytotoxicity in bulk culture. The degree of cytotoxicity for the donor EBV-BLCL correlated with the log of the EBV-CTLp frequency (at 3 months, r = .60; 95% CI, 0.35 to 0.86). Too few observations were recorded at 6 months posttransplant to permit informative analyses for that time point.
To determine whether and to what degree the posttransplant interval associated with severe deficiencies of EBVspecific cellular immunity observed early posttransplant coincided with the period of risk for developing EBV-LPD, we examined the medical records of 655 patients who received allogeneic bone marrow transplants for leukemia at Memorial Sloan-Kettering Cancer Center (MSKCC; New York, NY) between January 1,1987, and March 1,1995; of whom, 28 developed EBV-associated lymphomas (4.3%). In this series, the cause-specific estimates of EBV-LPD in recipients of SBA-E-TCD grafts from related or unrelated donors treated with ATG and/or steroids were 6.7% and 18.3%, respectively. Among those patients who received SBA-Egrafts who were not treated with ATG or steroids, the causespecific estimate was 0.8%. There were no EBV lymphomas in recipients of unmodified transplants. As shown in Fig 3  (bottom panel) , all cases of EBV-LPD developed between 1 and 7.4 months posttransplant, with the peak being at 3 months post-BMT. 
EBV-LPD Post BMT (Months)
One recipient of a TCD, HLA-identical sibling BMT developed an EBV lymphoma at 4 months posttransplant. As shown in Fig 5A (top panel) , T cells isolated from this patient before donor leukocyte infusion did not induce lysis of donor EBV-BLCL in bulk culture; by limiting dilution analysis (Fig 5A, bottom panel) , the frequency of EBV-specific CTLp was 1/119,150, which is in the intermediate range. Based on preinfusion CTLp frequencies in this patient, and assuming that the blood volume is approximately 8% of body weight and that lymphocytes in the peripheral blood constitute 2% of total body lymphocytes:o UPN 1461 had a total of 1.64 X lo6 EBV CTLp before infusion and 17.9 X lo6 EBV-specific CTLp at 2 weeks postinfusion. This indicates that there was an 10.9-fold increase in the number of EBV CTL generated in this patient within 2 weeks of the donor leukocyte infusion. By 2 months after PBMC infusion (Fig 5C) , the EBV CTLp frequency was 111,580. At this time, there was 81% specific lysis of the autologous BLCL and some cytotoxicity against the unrelated BLCL target JL, which shared the HLA antigens A26, B14, and DR7 with this patient. The cytotoxicity against the donor EBV-transformed autologous BLCL and the BLCL JL could be largely inhibited by pretreatment of effector cells with anti-CD3.
DISCUSSION
EBV-induced lymphomas have recently emerged as a significant complication of HLA nonidentical related and matched unrelated marrow allografts, particularly when the allografts are administered after selective depletion of T cells with certain monoclonal antibodie~~-'.''.'~ or application of more intensive T cell-targeted immunosuppressive regimens to ensure engraftment or prevent GVHD?" These EBV-LPD most often present as high-grade diffuse large cell malignant B-cell lymphomas which are oligoclonal or monoThese lymphomas express not only EBNA-l but also EBNA-2, EBNA-3 and LMP-1.8 Their clinical course is fulminant and usually fata1.3-5.1 ',12 A striking feature of the EBV lymphomas emerging in marrow allograft recipients is that they are almost invariably of marrow donor rather than host rigi in.^^*^" Furthermore, as illustrated in Fig 3, these lymphomas arise only in the period between the initiation of engraftment (approximately 1 month posttransplant) and 6 to 8 months posttransplant, at which time, early reconstitution of T-and B-cell populations of donor origin is usually appreciated.31332 These malignancies have, therefore, been hypothesized to result from rapid emergence of EBV-transformed B-cell clones from the marrow graft itself, at a time when lymphoid cells potentially capable of restricting the growth of these cells are presumably at their nadir.
The present study was designed to analyze and quantitate the recovery of EBV-specific T cells after a marrow allograft and to correlate this recovery with susceptibility to EBV-LPD. The effector cells examined in this study were predominantly T lymphocytes. NK cells were selectively depleted from the effector cell preparations. The T cells exhibited cytotoxicity that was specific for autologous, EBV-infected BLCL. Uninfected, autologous PHA blasts and EBV-BLCL derived from fully allogeneic donors were not lysed. Furthermore, these cytolytic responses could be almost completely inhibited by preincubating the T cells with anti-CD3. Although a small number of NK cells was present in most preparations, the frequency of cytotoxic cells capable of lysing allogeneic BLCL in these patients at all study intervals was 1/145,000 or less (data not shown). Thus, the contribution of major histocompatibility complex (MHC)-nonrestricted cells to the in vitro cytolysis of EBV-BLCL observed was small.
Recipients of both unmodified and TCD bone marrow allografts are known to have severe quantitative and qualitative deficiencies of T cells capable of mitogen-or antigeninduced proliferation for several months post-BMT.3".'2 The present study of T lymphocytes from BMT patients reveals that the majority of these patients also have profound deficiencies of EBV-specific cytotoxic T cells at 3 months after transplant. However, EBV-specific cytotoxic T-cell populations, as measured by levels of EBV-specific cytotoxicity detected in standard 5'Cr assays and quantitation of EBVspecific CTLp frequencies, approximate those in normal seropositive adults by 6 months posttransplant. Using standard assays of cell-mediated cytolysis, Crawford et aP3 also found that in recipients of unmodified BMT, 7 of 10 patients studied had defective killing of the autologous BLCL at 3 months posttransplant, while all 10 patients had normal killing by 6 months post-BMT.
As shown in Fig 3, the interval during which profound deficiencies of EBV-specific cytotoxic T cells are observed closely corresponds with the time period in which patients are at risk for EBV-LPD. Given the suggested contribution of a more profound immunodeficiency posttransplant to EBV-LPD susceptibility in recipients of SBA-E TCD grafts, we were surprised to find that deficiencies of EBV CTLp observed in recipients of unmodified marrow grafts at 3 months posttransplant were as frequent and quantitatively as severe as those detected in recipients of SBA-E-TCD grafts.
Recipients of SBA-E-TCD grafts only receive total clonable T-cell doses ranging between 2 X IO4 and 10 X IO4 T cells per k i l~g r a m , '~ doses that are 500-to 1,000-fold lower than those transferred in an unmodified graft. Based on the frequencies of EBV CTLp detected in normal seropositive donors, the number of EBV-specific CTLp infused with an SBA-E-TCD graft would be expected to be quite small. As a result, the capacity of such patients to generate an adequate response to an EBV oligoclonal proliferation may be markedly inferior to that of a recipient of an unmodified graft and may be even more profoundly compromised by posttransplant immunosuppression. Despite this, 8 of 11 recipients of SBA~ E-BMT in this series developed frequencies of EBV CTLp by 6 months posttransplant that were well in the range of seropositive normals. This suggests that despite the limited number of EBV CTLp transferred in the graft, most recipients of either unmodified or SBA E-TCD grafts are able to generate strong virus-specific responses by 6 months posttransplant that are likely to be effective in controlling or suppressing EBV-induced lymphoproliferations.
Prospective analyses of large populations of patients transplanted with unmodified or TCD marrow will be required to determine definitively whether or not the dose of EBVspecific CTLp administered in a graft, the rapidity of recovery of EBV-specific immunity or the level of EBV-specific immunity achieved in recipients of unmodified grafts differs significantly from that of recipients of TCD grafts and whether such deficiencies are correlated with susceptibility to EBV-LPD. Nevertheless, while the number of patients evaluated in this study is too small for statistical analysis, the lack of any apparent difference between the two groups in the frequency of EBV-specific cytotoxic T-cell precursors or their virus-specific cytotoxic activity at 3 months or 6 months posttransplant suggests that other factors must also be considered to explain the differential susceptibility to EBV-LPD observed. For example, during the acute phase of infectious mononucleosis, both MHC-nonrestricted and MHC-restricted EBV-reactive T cells, as well as NK cells, have been implicated in the initial cellular immune response to the EBV virus.'5 Previous studies from our group have shown that recovery of IL-2-activated NK cell populations and their lytic activity against susceptible targets such as K562 occur as early as 3 weeks posttransplantation and is equivalent in recipients of unmodified and SBA-E-TCD marrow grafts." However, it is possible that NK cells emerging after an SBA-E-graft might not be as effective in limiting the expansion of EBV-BLCL emerging early in the posttransplant period. Analyses to address this issue are planned. Alternatively, the more prolonged deficits in 1L-2 production by T cells that we have demonstrated in recipients of SBA E-grafts might limit the capacity of the transplant recipient to activate NK cells or expand EBV-reactive Tcell populations sufficiently to induce lysis and thereby control the proliferation of EBV-transformed targets."
The specific features of host, donor, or viruses that instigate the development of oligoclonal or monoclonal EBV-LPD in a subset of these immunodeficient patients early posttransplant remain a conundrum. It is possible that TCD transplants from donors without prior exposure to EBV or who maintain only a low level of residual EBV-specific Tcell immunity do not confer populations of EBV-reactive For personal use only. on November 11, 2017 . by guest www.bloodjournal.org From T cells sufficient to mount a response of the magnitude necessary to limit proliferation of EBV-transformed B cells emerging early posttransplant. In support of this possibility are studies of patients developing EBV-LPD after organ allografts, which have demonstrated an increased risk of EBV-LPD among EBV-seronegative transplant recipients." It is also possible that lymphomagenesis occurs only in patients exposed to more lymphomagenic EBV strain^^^,^" or to high doses of lytic virus4' as a result of transfusions administered in the early posttransplant period. Similarly, it is possible that coinfection with another facilitating virus contributes to lymphomagenesis, as has been suggested by recent studies of EBV+ lymphomas in AIDS patients who also have herpes simplex ~i r u s -8 .~~
That EBV-specific T cells can eradicate established EBVinduced lymphomas was initially suggested by our studies demonstrating that infusions of small doses of PBMC from a patient's EBV-seropositive marrow donor could consistently induce prompt and durable remissions of EBV-induced monoclonal lymphomas developing in recipients of TCD marrow graftsis Direct demonstration of the capacity of adoptively transfused EBV-specific cytotoxic T cells to induce regressions of disease has subsequently been demonstrated in murine xenograft models of EBV-LPD by Boyle et a143 and Lacerda et ala in a human EBV-LPD xenograft model in the SCID mouse, and by Rooney et a145 and Servida et a1,"6 who administered small numbers of in vitro-expanded, genetically marked, EBV-specific T cells and thereby induced regressions of EBV-LPD in human marrow allograft recipients.
In each of our cases successfully treated by adoptive transfer of donor-derived PBMC or cultured EBV-specific T cells, the onset of regressions of EBV-induced lymphomas has been detected by clinical and radiologic criteria as early as 2 to 4 weeks after PBMC infusion. As early as 7 days postinfusion of donor PBMC providing as few as 0.5 X lo6 to 1 .O X l O6 T cells per kilogram, tumor cells may be almost completely eradicated from biopsied tumors and involved lymph nodes.I5 The residual cells in these tissues consist of histologically normal stromal elements and T lymphocytes. Because of the rapidity and extent of the clinical and pathologic responses observed, we were particularly interested in quantitating the effects of donor PBMC infusions on EBVspecific cell-mediated immune responses during this time period. As shown in one patient treated for an EBV lymphoma (Fig SA and B) , an infusion of donor PBMC providing 0.5 X lo6 T cells per kilogram and a calculated dose of 818 (95% CI, 625 to 1,182)26 EBV-specific T-cell precursors led to the development of large populations of HLA-restricted EBV-specific T cells within 2 weeks of their infusion. During this interval, the frequency of EBV CTLp detected in the circulation increased more than 10-fold. If this increment was based solely on the expansion of the EBV CTLp infused with the donor PBMC, this would represent a 20,000-fold amplification of the adoptively transferred EBV CTLp. To distinguish between the contributions of the adoptively transferred EBV CTLp and EBV-reactive T cells that may be recruited from T-cell populations developing within the transplanted host, it will be necessary to genetically mark the adoptively transferred EBV CTLp and assess, quantitatively, the proportion of adoptively transferred cells in the EBV-specific T-cell populations that emerge after their transfer. Strategies using retroviral vectors for transfection of in vitro-generated EBV-specific T cells have been developed by Servida et a146 and Rooney et a145 and are currently being used by Servida et ar6 to address this issue.
While the determination of EBV CTLp frequencies using limiting dilution analysis is a sensitive measure of EBV cytotoxic capacity, the use of bulk cytotoxicity assays provides useful information and is well correlated with CTLp frequency as a measure of the presence or absence of anti-EBV immunity in normal seropositive and seronegative individuals (Fig 2) . As demonstrated in Fig 3, patients with CTLp frequencies in the range of seronegative donors also had an absence of EBV-specific cytotoxicity in bulk culture, while patients with CTLp in the range of seropositive donors also were positive in bulk culture assays. Four patients with CTLp in the intermediate range lacked bulk culture cytotoxicity, while the remaining four patients had positive bulk culture cytotoxicity. If the bulk culture assay for EBV immunity was to be used as the only assay for prediction of emerging cellular immunity to EBV, we would have classified the four patients with intermediate CTLp but negative bulk culture cytotoxicity as patients at risk, while the four patients with intermediate CTLp and positive bulk culture would be classified as patients with cellular immunity to EBV. It is interesting to note that the one patient in this study group who developed an EBV-LPD during the study period, in fact, had CTLp in the intermediate range (111 19,150) but lacked detectable bulk culture cytotoxicity. Thus, in highrisk BMT patients, the latter assay might be sufficient to determine which patients have clinically significant deficiencies of cellular immunity to EBV. LDA may be a useful assay to perform on bone marrow donors before transplant to anticipate which patients are receiving fewer EBV-specific CTL with their graft. Such patients may be candidates for prophylactic leukocyte or EBV-CTL infusions. LDA is a useful assay for monitoring the effects of these donor leukocyte infusions in vitro.
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